valsartan has been researched along with ag-490 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, ZY; Shan, C; Wu, H; Yu, J; Zhang, KQ; Zhu, Q | 1 |
| Cai, SY; Fu, YL; Lin, Q; Peng, FH; Tao, L; Wang, Q; Zheng, NZ | 1 |
2 other study(ies) available for valsartan and ag-490
| Article | Year |
|---|---|
Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Chemokine CXCL9; Diabetic Nephropathies; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Membrane Proteins; Mice; Podocytes; Proto-Oncogene Proteins c-bcl-2; Receptors, Angiotensin; Receptors, CXCR3; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Tyrphostins; Valsartan | 2017 |
GJA1-20k attenuates Ang II-induced pathological cardiac hypertrophy by regulating gap junction formation and mitochondrial function.
Topics: Angiotensin II; Animals; Cardiomegaly; Connexin 43; Down-Regulation; Gap Junctions; Janus Kinase 2; Male; Membrane Potential, Mitochondrial; Mitochondria; Myocardium; Organelle Biogenesis; Rats, Inbred WKY; Reactive Oxygen Species; Signal Transduction; Tyrphostins; Valsartan | 2021 |